Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer

NCT06134271 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Hormone-Sensitive Prostate Cancer

Interventions

DRUG: Rezvilutamide
DRUG: Rezvilutamide plus abiraterone
DRUG: Continue previous treatment

Sponsor

Jianbin Bi